Recent news includes NovelStem's 2022 results filing, collaborations to validate diagnostic devices, and strategic repositioning announcements. The company has also completed liquidation of NewStem and settled litigation funding liabilities through asset sales.

• NovelStem reported 2022 results focused on its patented genetic platform technology for anti-cancer therapies in a Form 10-K filing [N8].
• NovelStem's affiliate NewStem announced a collaboration to validate its software diagnostic device for oncology indications and therapies [N8].
• NovelStem secured commitment for up to $600K in bridge funding and provided a financial update as an SEC-reporting company [N8].
• NovelStem announced material developments and strategic repositioning of the company in May 2025 [N8].
• NovelStem completed liquidation of NewStem in October 2025, with the technology license reverting to Yissum and NovelStem retaining financial interest [S1].
• NovelStem sold its 50% interest in NetCo Partners in May 2025 to settle litigation funding liabilities [S1].

NovelStem's retained financial interest in the exclusive license from Yissum for stem cell-based oncology technology could provide future revenue streams if the license is successfully commercialized by future licensees. The company's prior investments and collaborations in biotech research and diagnostics demonstrate a foundation in innovative medical technology. The divestiture of the NetCo joint venture settled significant debt, potentially improving financial flexibility.

NovelStem has experienced operational challenges, including the liquidation of NewStem due to inability to raise funds for continued research and development. The company reported net losses and holds limited liquidity with a current ratio of 0.03 as of June 2026, indicating potential financial distress. The success of future license monetization is uncertain and subject to regulatory approvals and competitive pressures. The company has no employees and relies on consultants, which may limit operational capacity.

NovelStem's moat was primarily based on its equity interest in NewStem and the exclusive license to proprietary stem cell technology for oncology applications. However, with NewStem's liquidation and the license reverting to Yissum, NovelStem's moat now depends on its retained financial interest in future monetization of the license. The company's prior involvement in the Net Force franchise was divested in 2025. The biotech technology underlying the license faces rapid technological change and competition, which may impact future value.

• Financial Viability: The company has reported net losses and holds limited current assets relative to liabilities, raising concerns about its ability to continue as a going concern without additional financial support.
• Dependence on License Monetization: NovelStem's principal asset is a financial interest in a license held by Yissum; the company's future revenue depends on successful commercialization by third parties, which is uncertain.
• Regulatory and Competitive Risks: The underlying biotech technology is subject to extensive FDA and international regulatory requirements and faces rapid technological change and competition, which could adversely affect future licensing revenues.
• Operational Capacity: NovelStem has no employees and relies on consultants, which may limit its ability to execute strategic initiatives independently.

• NovelStem International Corp. is a holding company whose principal asset is rights to profits from a license held by Yissum Research Development Company, Hebrew University's technology transfer company, previously held through its ownership interest in NewStem Ltd.
• NovelStem owned approximately 31% equity interest in NewStem Ltd, an Israeli biotech company, which was liquidated in October 2025, with the technology license reverting to Yissum and NovelStem retaining financial interest in future licensing.
• NovelStem owned a 50% interest in NetCo Partners, a joint venture owning the Net Force publishing franchise, which was sold in May 2025 to settle litigation funding debt.
• NewStem was focused on stem cell-based biotechnology, specifically haploid human pluripotent stem cells, with applications in cancer research, regenerative medicine, and disease therapy.
• NewStem developed a discovery bio-platform for genome-wide screenings and oncology drug discovery based on synthetic lethal interaction, and a personalized diagnostic for early detection of chemotherapy resistance.
• NewStem's technology was based on an exclusive worldwide license from Yissum and The New York Stem Cells Foundation, with royalty obligations up to 3% of net sales and up to 12% of sublicense consideration.
• NewStem filed an FDA Pre-Submission and received a CE Mark from the European Medicines Agency for its in vitro diagnostic device, but does not have FDA approval for a medical device.
• NovelStem was the original seed investor in NewStem, providing $4 million in funding from 2018 to 2021, and owned 30.51% equity at liquidation.
• NovelStem has no employees and relies on consultants for operations.
• NovelStem reported net losses of approximately $2.38 million and $3.23 million for the years ended December 31, 2025 and 2024, respectively.
• As of June 30, 2026, NovelStem had cash and equivalents of $1,106 and current assets of $64,687, with current liabilities of $2,097,158, resulting in a current ratio of 0.03 and a cash ratio of 0.
• NovelStem's continuation as a going concern depends on improving profitability and financial support from shareholders and Yissum's ability to commercialize the license.
• NovelStem's business focus shifted from media to biotech with the acquisition of NewStem in 2018, but NewStem ceased operations in October 2024 and was liquidated in October 2025.
• NovelStem's principal operations coincided with those of NewStem until its liquidation.
• NovelStem's financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.